CPRX Earnings

CPRX reported its FY2025Q4 earnings on 2026-03-12, showcasing a revenue of against an estimate of 137.08M, resulting in a 0% surprise. The EPS was 0, surpassing the expected 0.47 by 0%. The stock experienced a 0% price change on the earnings day and a 0% change over the next five days, reflecting market reactions to the results.

Following CPRX's FY2025Q4 earnings announcement on 2026-03-12, the stock price moved by 0% on the day of the release. Over the subsequent five days, it saw a 0% change. Historically, CPRX's stock price tends to shift by an average of -0.86% in the 10 days leading up to earnings and 2.5% in the 10 days following, providing insight into potential market.

For 2026/Q1, analysts estimate CPRX's annual revenue to reach 142.40M, while the EPS is projected at 0.37. These estimates reflect recent revisions, with revenue estimates unchanged by 0% and EPS estimates unchanged by 0% over the past three months, indicating analyst expectation in the company's performance.

The correlation between CPRX's stock price and earnings forecast revisions shows that positive revisions in revenue or EPS often strengthen the stock's fundamentals. Over the past three months, revenue estimates for FY2025 were unchanged by 0%, while EPS estimates moved unchanged by 0%. This trend suggests that price dips could present buying opportunities for investors.

Based on historical trends, CPRX's stock price typically moves by -0.86% in the 10 days before its earnings and 2.5% in the 10 days after. For the upcoming 2026/Q1 earnings, analysts expect an EPS of 0.37 and revenue of 142.40M.

The earnings call summary reflects strong financial performance, with significant revenue growth across products and increased guidance for 2025. The Q&A session highlighted effective strategies for growth, such as pharmacy intervention programs and increased VGCC testing, which support optimistic future prospects. While management avoided specifics on business development deals, the overall sentiment is positive with robust financial health and strategic initiatives in place. Given the market cap of $1.78 billion, the stock is likely to react positively to these developments, with a predicted stock price increase of 2% to 8%.